A Case-control Study on the Clinical Characteristics of 28-day and 90-day Death From Severe Anthrax

Launched by QIN NING · Apr 10, 2024

Keywords

ClinConnect Summary

This clinical trial is studying severe anthrax, a serious infection caused by bacteria, to better understand the characteristics of patients who survive or do not survive after 28 days and 90 days. Researchers will look at various health information from patients diagnosed with severe anthrax, including their vital signs, blood tests, and overall health during their hospital stay. They aim to see how these factors relate to survival both shortly after treatment and a few months later.

To participate in this study, patients must be diagnosed with severe anthrax and show signs of multiple organ dysfunction, which means that more than one organ in their body is not working properly. The study is open to all adults aged 65 and older. Participants will have their health data reviewed, and the findings may help improve future treatments for severe anthrax. It’s important to note that individuals with other serious health conditions that could affect their survival are not eligible to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. The typical bacilli with capsules were found in smear examination and culture of various secretions, excretions, blood and cerebrospinal fluid.
• • 2. Multiple organ dysfunction (MODS) in brain, heart, liver, kidney, coagulation or more than one organ failure.
• Exclusion Criteria:
• • There are other conditions that affect short-term survival.